Stocktoria
GALECTIN THERAPEUTICS INC GALT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2002-09-04
GALECTIN THERAPEUTICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M |
| Interest expense | — | — | $2.8M | $1.0M | $489,000 |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M | -$30.5M |
| EPS (diluted) | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 |
| Operating cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M |
| Cash & equivalents | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M |
| Shareholders' equity | -$127.9M | -$104.8M | -$62.0M | -$33.9M | $893,000 |
Source: SEC EDGAR filings · CIK 0001133416 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.